192 related articles for article (PubMed ID: 34213608)
1. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
Jalali MM; Saedi HS; Saadat F
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
[TBL] [Abstract][Full Text] [Related]
2. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
4. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
5. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
7. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
8. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.
Ozturan O; Jerger J; Lew H; Lynch GR
Auris Nasus Larynx; 1996; 23():147-51. PubMed ID: 8809338
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity from cisplatin therapy in childhood cancer.
Coradini PP; Cigana L; Selistre SG; Rosito LS; Brunetto AL
J Pediatr Hematol Oncol; 2007 Jun; 29(6):355-60. PubMed ID: 17551394
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
13. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
14. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
15. Test-retest reliability of distortion-product thresholds compared to behavioral auditory thresholds.
Bader K; Dierkes L; Braun LH; Gummer AW; Dalhoff E; Zelle D
Hear Res; 2021 Jul; 406():108232. PubMed ID: 33984603
[TBL] [Abstract][Full Text] [Related]
16. Subclinical diagnosis of cisplatin-induced ototoxicity with biomarkers.
Generotti C; Cox BC; Singh J; Hamilton D; McKenzie E; O'Malley BW; Li D
Sci Rep; 2022 Oct; 12(1):18032. PubMed ID: 36302835
[TBL] [Abstract][Full Text] [Related]
17. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment.
Toral-Martiñón R; Shkurovich-Bialik P; Collado-Corona MA; Mora-Magaña I; Goldgrub-Listopad S; Shkurovich-Zaslavsky M
Arch Med Res; 2003; 34(3):205-8. PubMed ID: 14567400
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
19. Utilizing prestin as a predictive marker for the early detection of outer hair cell damage.
Dogan M; Sahin M; Cetin N; Yilmaz M; Demirci B
Am J Otolaryngol; 2018; 39(5):594-598. PubMed ID: 30025743
[TBL] [Abstract][Full Text] [Related]
20. Reliability of Serological Prestin Levels in Humans and its Relation to Otoacoustic Emissions, a Functional Measure of Outer Hair Cells.
Parker A; Parham K; Skoe E
Ear Hear; 2021; 42(5):1151-1162. PubMed ID: 33859120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
